AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.7% – Here’s Why

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) dropped 5.7% on Tuesday . The stock traded as low as $19.80 and last traded at $20.02. Approximately 174,378 shares traded hands during mid-day trading, a decline of 85% from the average daily volume of 1,165,128 shares. The stock had previously closed at $21.22.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Wedbush restated an “outperform” rating and set a $40.00 price target on shares of AnaptysBio in a research note on Wednesday, February 12th. JPMorgan Chase & Co. reduced their target price on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research note on Thursday, December 19th. BTIG Research downgraded shares of AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Wells Fargo & Company increased their price target on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Finally, Guggenheim cut their target price on AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $37.45.

AnaptysBio Stock Down 6.8 %

The company has a market cap of $601.91 million and a price-to-earnings ratio of -3.25. The company has a fifty day simple moving average of $15.71 and a two-hundred day simple moving average of $25.54.

Insider Buying and Selling

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 65,184 shares of the business’s stock in a transaction on Monday, December 30th. The stock was bought at an average price of $12.92 per share, for a total transaction of $842,177.28. Following the completion of the transaction, the director now owns 7,860,180 shares in the company, valued at approximately $101,553,525.60. The trade was a 0.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

Several large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. lifted its stake in AnaptysBio by 11.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 644 shares in the last quarter. Virtus ETF Advisers LLC lifted its position in shares of AnaptysBio by 24.7% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 936 shares in the last quarter. Rhumbline Advisers lifted its position in shares of AnaptysBio by 3.8% in the fourth quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company’s stock valued at $398,000 after acquiring an additional 1,111 shares in the last quarter. nVerses Capital LLC boosted its stake in shares of AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 1,400 shares during the last quarter. Finally, Values First Advisors Inc. purchased a new stake in AnaptysBio during the 3rd quarter worth about $49,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.